Abstract
The purpose of this study was to explore lymphocyte subsets of newly diagnosed DLBCL patients, and dynamics along with treatment of R-CHOP. A total of 40 DLBCL patients were enrolled. ALC of grade III-IV DLBCL patients was significantly lower than that of health controls (1.33*10E9/L vs 1.89*10E9/L, p = 0.003), mostly attributing to decreased CD4+ cells (p = 0.012). And serum LDH level of patients was negatively correlated with ALC (p = 0.033). ALC progressively decreased along with treatment, so as to CD3+, CD4+ and CD19+ cells, while proportion of CD4+ and CD8+ cells increased significantly after two cycles' treatment (p < 0.05). CR of ALC low (<1.18*10E9/L) group was lower than that of ALC high group (37.5% vs 73.3%), though not statistically significant (p = 0.179).
Keywords:
CD16 + CD56+ cells; CD19+ cells; CD4+ cells; CD8+ cells; DLBCL; lymphocyte subsets.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents, Immunological / administration & dosage
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols
-
Biomarkers
-
Case-Control Studies
-
Cyclophosphamide
-
Doxorubicin
-
Female
-
Humans
-
Immunophenotyping
-
Lymphocyte Count*
-
Lymphocyte Subsets* / drug effects
-
Lymphocyte Subsets* / metabolism
-
Lymphoma, Large B-Cell, Diffuse / blood
-
Lymphoma, Large B-Cell, Diffuse / diagnosis*
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Male
-
Middle Aged
-
Molecular Targeted Therapy
-
Neoplasm Staging
-
Prednisone
-
Retreatment
-
Rituximab / administration & dosage
-
Rituximab / adverse effects
-
Rituximab / therapeutic use*
-
Treatment Outcome
-
Vincristine
Substances
-
Antineoplastic Agents, Immunological
-
Biomarkers
-
R-CHOP protocol
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone